Translate this page into:
Pretargeting in Radio Bio-Conjugate Therapy: With Reference to “Rhenium, Gold & Lutetium as Candidate Therapy Isotopes”
Correspondence to: Pankaj Garg C/o Prof. D.K. Hazra, 12/123, Nai Ki Mandi, Katra Hathi Shah, Agra. Phone-0562-2264303, Email: pankajgarg20042000@yahoo.co.in
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Radiobioconjugate therapy is an emerging modality for Cancer in addition to conventional surgery, chemotherapy & external radio-therapy. The central problem of radio-bioconjugate therapy is the small fraction of radio-bioconjugate localized in the tumour. Pretargeting is one approach to maximize targeting in which an antibody construct, having a dual affinity both for tumour associated antigen as well as for a radio-labeled moiety is first administered followed by the radio-labeled moiety, which may be either biotin or a metal chelate. The relative merits of these are described & Rhenium-Re 186/188, Gold-Au199 & Lutetium-Lu177 are suggested as candidate therapy isotopes in such pretargeting approaches.
